Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Novartis (NVS - Snapshot Report) recently announced positive results on Afinitor, from a phase III trial, BOLERO-3. The study is evaluating Novartis’ Afinitor plus Roche’s (RHHBY - Analyst Report) Herceptin and vinorelbine for the treatment of women suffering from HER2 positive (HER2+) advanced breast cancer.

It was observed in the trial (n= 569) that Afinitor plus Herceptin and vinorelbine significantly extended progression-free survival (PFS) after prior therapy vis-à-vis placebo plus Herceptin and vinorelbine.

Novartis will present detailed results at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO).

Novartis estimates that approximately 140,000 women are suffering from HER2 positive advanced breast cancer across the world.

Hence, the successful development and commercialization of Afinitor for the above-mentioned indication will further boost the sales potential of the drug. Afinitor generated sales of $797 million in 2013, up 85% year over year.

We remind investors that Afinitor is already approved in the US and EU (trade name: Votubia) for the treatment of advanced renal cell carcinoma following vascular endothelial growth factor-targeted therapy along with other indications.

In 2012, Afinitor received approval from both European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of HR+/HER2- advanced breast cancer in combination with Pfizer’s (PFE - Analyst Report) Aromasin, in postmenopausal women whose disease has returned or progressed even after undergoing treatment with a non-steroidal aromatase inhibitor.

We note that Afinitor is an important part of Novartis’ portfolio and are pleased with the company’s efforts to expand the label.

Novartis currently carries a Zacks Rank #3 (Hold). Right now, Salix Pharmaceuticals (SLXP - Analyst Report) looks attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%